News
QGEN
40.00
+1.34%
0.53
Bank of America Securities Reaffirms Their Buy Rating on Qiagen (QGEN)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)
TipRanks · 3d ago
Deutsche Bank Remains a Buy on Qiagen (QGEN)
TipRanks · 4d ago
Weekly Report: what happened at QGEN last week (0408-0412)?
Weekly Report · 5d ago
QIAGEN N.V. to release results for Q1 2024 and hold webcast
QIAGEN N.V. Announced plans to release results for the first quarter 2024. The company will release results on Monday, April 29, 2024. QIAGEN will be listed on the NYSE and the FTSE 100 in the Netherlands and in Germany.
Barchart · 04/09 08:48
Weekly Report: what happened at QGEN last week (0401-0405)?
Weekly Report · 04/08 09:25
Are Qiagen N.V.'s (NYSE:QGEN) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Qiagen's 9.0% return on equity is a key measure of a company's profitability. Qiagen's ROE is lower than the industry average for its industry. The company grew its net income by 30% in the last five years. Its stock has declined 12% over the past three months. The ROE of Qiagen shows the company is reinvesting its profits to grow.
Simply Wall St · 04/07 14:13
QIAGEN (QGEN) Boosts Cancer Research Suite With New Launches
NASDAQ · 04/04 17:22
Qiagen Becomes Oversold (QGEN)
NASDAQ · 04/04 15:54
Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Bio-Techne is a life science tools and services company focused on the development and sale of reagents and consumables for life science research. The company's focus on the stable and lucrative life science market has led to above-average growth and profitability compared to diagnostic companies. Bio- techne has exhibited strong financial performance, with high profit margins and low leverage. Healthcare is a strong sector for secular growth, but life science is more stable than diagnostics.
Seeking Alpha · 04/04 12:43
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024
Barchart · 04/03 15:05
Weekly Report: what happened at QGEN last week (0325-0329)?
Weekly Report · 04/01 09:24
QGEN Makes Notable Cross Below Critical Moving Average
NASDAQ · 03/25 21:07
QIAGEN (QGEN) Partners With IPPA to Raise TB Screening Awareness
NASDAQ · 03/25 13:10
Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test
NASDAQ · 03/25 11:03
Weekly Report: what happened at QGEN last week (0318-0322)?
Weekly Report · 03/25 09:25
Revvity: Enter Now As Reorganization Takes Shape
Revvity, Inc. Is a major laboratory instrument and service provider to the healthcare industry. The company has historically underperformed compared to its peers in terms of profit generation and growth. Revvity has implemented a business restructuring plan and aims to drive differentiation through inorganic investments in high-margin areas. Over the past 20 years the company has returned 10.5% per year for investors.
Seeking Alpha · 03/21 15:27
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly
Qiagen N.V. Has US$1.61b of debt on its balance sheet, but is this a concern for shareholders? The company has a healthy balance sheet and is in a good position to pay off debt. Qiagen has a net debt of just 0.86 times its earnings. The company's free cash flow is 77% of what it produced in the last year. We look at Qiagen to see if its debt is a problem for shareholders.
Simply Wall St · 03/20 10:22
QIAGEN Partners With International Panel Physicians Association To Increase Awareness Of Tuberculosis Screening Requirements
QIAGEN announces partnership with the International Panel Physicians Association to support and educate panel physicians on the latest tuberculosis screening requirements. The CDC has updated its guidelines for new TB screening requirements for immigrants to the United States. QIAGEN and IPPA are committed to promoting the use of TB testing to ensure a safe immigration process.
Benzinga · 03/18 20:14
QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements
QIAGEN announces partnership with the International Panel Physicians Association to support and educate panel physicians on the latest tuberculosis screening requirements. A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and associated benefits for patients and healthcare providers. QIAGEN is a company of QGEN.
Barchart · 03/18 15:05
More
Webull provides a variety of real-time QGEN stock news. You can receive the latest news about Qiagen through multiple platforms. This information may help you make smarter investment decisions.
About QGEN
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.